BioCryst Pharmaceuticals Inc Virtual R&D Day Transcript
Good morning, and thank you for joining us for BioCryst's first virtual R&D Day. I'm John Bluth, Head of Investor Relations at BioCryst. And over the next 2 hours, we'll highlight for you how our unique approach and expertise in developing oral medicines for rare diseases has produced a full pipeline of molecules.
Today, we'll also focus on the exciting new data we've just announced with one of those molecules, our oral Factor D inhibitor, BCX9930, which we are now advancing into pivotal trials as a monotherapy for complement-mediated diseases. I do want to remind you that we will be making forward-looking statements, so please refer to the cautionary statement in the accompanying presentation slides and review the risk factors in our SEC filings, including in our most recent annual report on Form 10-K. These risk factors could cause actual results to be materially different from those experienced or implied in the forward-looking statements. Throughout the program today, we will introduce you to members
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
